Morgan Stanley analyst Adam Jonas downgrades Carvana (NYSE:CVNA) from Overweight to Equal-Weight and announces $105 price target.
Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $19
Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $17 to $19.